Date Range
Type of Content
Author
Category
Study
An Evaluation of the Proposed PMPRB Amendments
Federal government’s proposed drug changes mean potentially lower prices but reduced access and innovation
Study
Biologics and Biosimilars: A Primer
Canada’s comparatively weak intellectual property protections limit access to life-saving drugs
Study
Universal Insurance for Pharmaceuticals in Switzerland and the Netherlands
Governments continue to ignore positive health reform lessons of countries such as Switzerland and the Netherlands—including on pharmacare
Study
The Unintended Consequences of National Pharmacare Programs: The Experiences of Australia, New Zealand, and the UK
Lessons from the U.K., New Zealand and Australia indicate that government-run pharmacare limits access to new drugs, discourages innovation
Study
Implications of the proposed changes to Canada's pharmaceutical pricing regulations
Ottawa’s drug-pricing changes risk limiting patient access to new medicines
Study
Pharmaceutical Counterfeiting: Endangering Public Health, Society, and the Economy
Counterfeit pharmaceutical drugs put Canadian patients at risk
Study
Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up
Canada’s inadequate patent protections for pharmaceuticals hampering innovation and economic growth
Study
Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals
Stronger patent protections could lead to new life-saving drugs and lower costs for patients
Study
The Biologics Revolution in the Production of Drugs
Outdated and uncompetitive regulations limiting patient access, stunting investment in cutting-edge medicines in Canada
Study
The Benefits of Incremental Innovation
Incremental innovations in pharmaceutical industry spawn life-saving improvements